Volume | 889,669 |
|
|||||
News | - | ||||||
Day High | 12.55 | Low High |
|||||
Day Low | 12.20 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sage Therapeutics Inc | SAGE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
12.39 | 12.20 | 12.55 | 12.34 | 12.39 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
9,628 | 889,669 | $ 12.36 | $ 10,992,856 | - | 10.92 - 59.99 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:21:26 | 8 | $ 12.25 | USD |
Sage Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
741.72M | 60.11M | - | 86.46M | -541.49M | -9.01 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sage Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SAGE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 13.38 | 14.3089 | 12.20 | 13.15 | 773,348 | -1.13 | -8.45% |
1 Month | 16.66 | 16.81 | 10.92 | 13.71 | 1,313,424 | -4.41 | -26.47% |
3 Months | 26.50 | 26.50 | 10.92 | 17.50 | 1,025,562 | -14.25 | -53.77% |
6 Months | 18.52 | 28.26 | 10.92 | 20.16 | 955,651 | -6.27 | -33.86% |
1 Year | 51.28 | 59.99 | 10.92 | 24.65 | 1,111,385 | -39.03 | -76.11% |
3 Years | 74.88 | 79.45 | 10.92 | 33.98 | 776,765 | -62.63 | -83.64% |
5 Years | 168.84 | 193.56 | 10.92 | 49.01 | 757,509 | -156.59 | -92.74% |
Sage Therapeutics Description
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development. |